Trichoscopy of Steroid-Induced Atrophy

Rodrigo Pirmez^a Leonardo S. Abraham^b Bruna Duque-Estrada^a
Patrícia Damasco^b Débora Cadore Farias^c Yanna Kelly^d Isabella Doche^d

^aDepartment of Dermatology, Instituto de Dermatologia Professor Rubem David Azulay, Santa Casa da Misericórdia do Rio de Janeiro, Rio de Janeiro, ^bDepartment of Dermatology, Hospital Regional da Asa Norte, Brasília, ^cDepartment of Dermatology, Universidade Federal de Santa Catarina, Florianópolis, and ^dDepartment of Dermatology, Universidade de São Paulo, São Paulo, Brazil

Keywords

Alopecia · Corticosteroid · Dermoscopy · Intralesional injection · Skin atrophy · Steroids · Trichoscopy

Abstract

Intralesional corticosteroid (IL-CS) injections have been used to treat a variety of dermatological and nondermatological diseases. Although an important therapeutic tool in dermatology, a number of local side effects, including skin atrophy, have been reported following IL-CS injections. We recently noticed that a subset of patients with steroid-induced atrophy presented with ivory-colored areas under trichoscopy. We performed a retrospective analysis of trichoscopic images and medical records from patients presenting ivory-colored areas associated with atrophic scalp lesions. In this paper, we associate this feature with the presence of steroid deposits in the dermis and report additional trichoscopic features of steroid-induced atrophy on the scalp, such as prominent blood vessels and visualization of hair bulbs.

© 2017 S. Karger AG, Basel

Introduction

Intralesional corticosteroid (IL-CS) injections have been used to treat a variety of dermatological and nondermatological diseases [1]. IL-CS injections are, for example, considered as a first-line therapy in patchy alopecia areata [2]. Although an important therapeutic tool in dermatology, a number of local side effects, including skin atrophy, have been reported following IL-CS injections [1]. We recently noticed that a subset of patients with steroid-induced atrophy presented with ivory-colored areas under trichoscopy (Fig. 1). In this paper, we associate ivory-colored areas with the presence of steroid deposits in the dermis and report additional trichoscopic features of steroid-induced atrophy. To the best of our knowledge, there are no other studies reporting such data.

Materials and Methods

We performed a retrospective analysis of trichoscopic images and medical records from patients presenting ivory-colored areas associated with atrophic scalp lesions. All patients had been seen for different types of hair loss, including both scarring and non-scarring alopecias, at 4 referral centers in Brazil. Diagnosis was established clinically by dermatologists with experience in hair dis-

Fig. 1. Ivory-colored areas seen under trichoscopy in an alopecia areata patient presenting corticosteroid-induced skin atrophy. Original magnification: $\times 20$.

orders and, in doubtful cases, was confirmed through pathology. Clinical information is summarized in Table 1. Trichoscopy and photographic documentation were performed using either FotoFinder Dermoscope®, FotoFinder Handyscope® (Teachscreen Software, Bad Birnbach, Germany), or DermLite® Foto (3Gen, San Juan Capistrano, CA, USA) attached to a Nikon® J1 camera.

Results

Twenty-five lesions from 8 patients were retrieved. All patients had been submitted to IL-CS injections as part of their treatment. In 3 patients, biopsies from ivory-colored areas were available and revealed circumscribed, fine pale foamy material in the dermis, suggestive of steroid deposits (Fig. 2) [3].

Another remarkable trichoscopic feature was the presence of prominent blood vessels in 23 (92%) lesions (Fig. 3), which were classified as thin (16 lesions; 64%) and thick arborizing (15 lesions; 60%) and which in 3 lesions (12%) were so numerous as to form a vascular network. Visualization of hair bulbs through the atrophic skin was evident in 5 lesions (20%) (Fig. 4a). Interestingly, in 5 (out of 12) lesions of patients with alopecia areata, regrowing hairs were organized as a collar that surrounded the steroid deposits (Fig. 4b).

During our research, another 8 patients with 13 similar lesions in areas other than the scalp were also identified. Such patients had also been submitted to IL-CS injections for different reasons (clinical information can be found in Table 2).

Table 1. Clinical information from patients with scalp lesions of steroid-induced atrophy presenting ivory-colored areas

Patient	Gender	Age, years	Lesions, n	Condition	Corticosteroid and concentration, mg/mL
1	f	30	7	AA	TH 10
2	f	26	1	HS	BD 5 + BDS 2
3	f	68	2	DLE	TH 10
4	f	41	2	AA	TA 10
5	m	28	2	AA	TH 20
6	f	74	1	LPP	TH 05
7	f	68	9	FFA	unknown
8	f	59	1	AA	unknown

AA, alopecia areata; HS, hypertrophic scar; DLE, discoid lupus erythematosus; LPP, lichen planopilaris; FFA, frontal fibrosing alopecia; TH, triamcinolone hexacetonide; BD, betamethasone dipropionate; BDS, betamethasone disodium phosphate; TA, triamcinolone acetate.

Discussion

The presence of steroid deposits has already been reported after triamcinolone injections in different body areas, such as the vocal cords and eyes [4, 5]. In our case series, the reason for such deposits can only be speculated on. However, it is remarkable that in 25 lesions (out of 28 in which the steroid used is known) the corticosteroid injected was triamcinolone hexacetonide, which is known to be much less soluble than other steroids, including triamcinolone acetate [6, 7]. Some authors have even considered triamcinolone hexacetonide to be unsuitable for intralesional injection due to its inordinately long half-life [1]. Furthermore, in the 25 lesions in which triamcinolone hexacetonide was used, concentrations were equal to or higher than 10 mg/mL in 24 lesions (96%), which could serve as an additional risk factor for steroid deposition and tissue atrophy. Another interesting point to consider is that triamcinolone hexacetonide should not be mixed with diluents or local anesthetics containing preservatives, such as parabens or phenols, since they may cause precipitation of the steroid [1]. Even though this information was not available, we cannot exclude that the type of diluent used may have played a role in the formation of cutaneous deposits in some cases.

Steroid-induced atrophy may be self-limited [8]. It is unknown whether the presence of steroid deposits in the dermis may hinder resolution of cutaneous atrophy. Ac-

Table 2. Clinical information from patients with body lesions of steroid-induced atrophy presenting ivory-colored areas

Patient	Gender	Age, years	Lesions, <i>n</i>	Body location	Condition	Corticosteroid and concentration, mg/mL
1	m	31	2	abdomen	HS	TH 20
2	f	32	2	face/chest	acne cysts	TH 20
3	f	70	2	arms	granuloma annulare	TH 20
4	f	34	1	inframammary	HS	TH 10
5	f	41	1	abdomen	HS	TH 20
6	f	35	2	abdomen/arm	HS	TH 20
7	f	32	2	breasts	HS	TH 20
8	m	32	1	chest	HS	TH 20

HS, hypertrophic scarring; TH, triamcinolone hexacetonide.

Fig. 2. Biopsies from ivory-colored areas revealed circumscribed, fine pale foamy material present in the dermis (a), which can be better visualized in b. HE staining. Original magnification: a $\times 100$ and b $\times 200$.

Fig. 3. Vascular changes in steroid-induced atrophy. Trichoscopy showed thin arborizing vessels (a), thick arborizing vessels (b), and blood vessels forming a vascular network (c). For classification purposes, vessels thinner than the average hair were considered as “thin” and vessels thicker than the average hair as “thick.” Original magnification: $\times 20$.

Fig. 4. Additional trichoscopic features included visualization of hair bulbs (a) and collars of regrowing hairs around the ivory-colored areas (b). Original magnification: $\times 20$.

cording to personal observations (B.D.-E. and L.S.A.), surgical removal of the deposits leads to partial regression of dermal atrophy, but prospective studies are necessary to confirm this information.

One limitation of the study was the limited access to patient data, since most of the patients were originally treated by other physicians. Information lacking includes the total number of injections received by each patient and the duration of atrophy.

In conclusion, we describe ivory-colored areas as a novel trichoscopic feature representing steroid deposits in the dermis and suggest that their presence may indicate the etiology of skin atrophy in cases in which a previous history of IL-CS injections is not clear. We further report additional features of steroid-induced atrophy on the scalp, such as prominent vessels and visualization of hair bulbs. Finally, we suggest the use of triamcinolone ace-

tonide rather than of its less soluble salt hexacetonide for intralesional injections and at lower concentrations, typically at 2.5 and 5 mg/mL for scalp lesions.

Statement of Ethics

All patients have given their consent for their details to be described in this article.

Disclosure Statement

The authors have no conflicts of interest to disclose.

Funding Sources

There were no funding sources for this work.

References

- 1 Firooz A, Tehranchi-Nia Z, Ahmed AR: Benefits and risks of intralesional corticosteroid injection in the treatment of dermatological diseases. *Clin Exp Dermatol* 1995;20:363–370.
- 2 Alkhalifah A, Alsantali A, Wang E, McElwee KJ, Shapiro J: Alopecia areata update: part II. Treatment. *J Am Acad Dermatol* 2010;62:191–202.
- 3 Kaur S, Amanjeet, Thami GP, Mohan H: Intralesional steroid induced histological changes in the skin. *Indian J Dermatol Venerol Leprol* 2003;69:232–234.
- 4 Wang CT, Lai MS, Hsiao TY: Comprehensive outcome researches of intralesional steroid injection on benign vocal fold lesions. *J Voice* 2015;29:578–587.
- 5 Okka M, Bozkurt B, Kerimoglu H, et al: Control of steroid-induced glaucoma with surgical excision of sub-Tenon triamcinolone acetonide deposits: a clinical and biochemical approach. *Can J Ophthalmol* 2010;45:621–626.
- 6 Garg N, Perry L, Deodhar A: Intra-articular and soft tissue injections, a systematic review of relative efficacy of various corticosteroids. *Clin Rheumatol* 2014;33:1695–1706.
- 7 Porter D, Burton JL: A comparison of intralesional triamcinolone hexacetonide and triamcinolone acetonide in alopecia areata. *Br J Dermatol* 1971;85:272–273.
- 8 Chang KH, Rojhirunsakool S, Goldberg LJ: Treatment of severe alopecia areata with intralesional steroid injections. *J Drugs Dermatol* 2009;8:909–912.